Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together have been shown to deliver superior efficacy in first-of-its-kind Phase IIIb trial for adults with active psoriatic arthritis (PsA) and obesity or who are overweight. 

At 36 weeks, treatment with concomitant Taltz and Zepbound met the primary and all key secondary endpoints for superiority to Taltz monotherapy.  

TOGETHER-PsA is the first controlled study to evaluate an incretin therapy used with a PsA biologic. An estimated 65% of adults with PsA in the US also have obesity (BMI ≥30kg/m²) or overweight (BMI 27-29.9kg/m²) with at least one additional weight-related comorbidity, highlighting a need for integrated treatment approaches that address the full burden of their diseases. 

In the study, 31.7% of patients in the Taltz plus Zepbound treatment arm achieved a 50% improvement in PsA activity, based on American College of Rheumatology 50 (ACR50), and weight reduction of at least 10%, compared to 0.8% of patients on Taltz monotherapy, meeting the primary endpoint.  

In a key secondary endpoint, Taltz plus Zepbound delivered a 64% relative increase over Taltz monotherapy in the proportion of patients who achieved ACR50 (33.5% of patients vs. 20.4%, respectively), demonstrating that treatment of obesity or overweight with Zepbound reduced the burden of PsA. 

PsA an obesity-related condition

Taltz is a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor.  

“While treatment guidelines for psoriatic arthritis recommend management of obesity, the reality is these two chronic diseases are often addressed separately and moving the needle in psoriatic arthritis has remained challenging,” said Joseph Merola, Professor and Chair, Department of Dermatology and Professor of Internal Medicine in the Division of Rheumatic Diseases, UT Southwestern Medical Center.  

“The observed benefit with treatment using Taltz and Zepbound appears to meaningfully impact psoriatic disease activity, indicating that for many patients, PsA is an obesity-related condition. This integrated therapy approach represents a potential paradigm shift and could lead to better outcomes for those living with both diseases.”

Diana Turner, Deputy Editor, DDW